Combining cannabinoids and opioids to reduce opioid use and overdose risks.
Development of cannabinoid-opioid combination with opioid sparing and synergistic analgesic effects to prevent opioid use disorder and overdose.
This study is looking to create a new pain relief treatment that combines cannabinoids and opioids to help manage chronic pain while reducing the chances of becoming dependent on opioids, so patients can find safer options for their pain management.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bdh Pharma, LLC NIH-funded |
| Lab location | 1 site (Studio City, UNITED STATES) |
| Project ID | NIH-10488729 on NIH RePORTER |
What this research studies
This research aims to develop a combination of cannabinoids and opioids that can provide effective pain relief while minimizing the risk of opioid use disorder and overdose. The approach involves creating a fixed-dose formulation that has shown promise in preclinical studies, demonstrating enhanced pain relief compared to opioids alone. By focusing on the pharmacokinetics and safety of this combination, the research seeks to offer a safer alternative for managing chronic pain and associated conditions. Patients may benefit from a new treatment option that addresses both pain and the risks of opioid dependency.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from chronic pain who are at risk of opioid misuse or dependency.
Not a fit: Patients who do not experience chronic pain or those who are not at risk for opioid use disorder may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a safer pain management option that reduces the likelihood of developing opioid use disorder.
How similar studies have performed: Other research has shown promising results with cannabinoid-opioid combinations, indicating potential for success in this area.
Where this research is happening
Studio City, UNITED STATES
- Bdh Pharma, LLC — Studio City, United States (Active)
Researchers
- Principal investigator: Briones, Marisa — Bdh Pharma, LLC
- Study coordinator: Briones, Marisa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.